Amphastar Pharmaceuticals (AMPH) PT Raised to $18 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014
March 24, 2015 4:01 PM EDTRANCHO CUCAMONGA, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) ("Amphastar" or the "Company") today reported results for the fourth quarter ended December 31, 2014.
Net revenues of $55.9 million for the fourth quarter GAAP net loss of $2.5 million, or $0.06 per diluted share for the fourth quarter Adjusted non-GAAP net loss of $1.5 million, or $0.03 per diluted share for the fourth quarter  Three Months Ended December 31, Years Ended December 31,  2014 2013 2014 2013  (in thousands, except per share data) Net revenues... More